- ISIN
- US0008991046
- CUSIP
- 000899104
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Oct 17, 2013
Highlights
- Market Cap
- $2.06B
- Enterprise Value
- $2.13B
- EPS (TTM)
- $0.68
- PE Ratio
- 12.66
- Total Revenue (TTM)
- $509.86M
- Gross Profit (TTM)
- $312.42M
- EBITDA (TTM)
- $218.74M
- Year Range
- $7.21 - $20.46
- Target Price
- $22.50
- ROA (TTM)
- 24.86%
- ROE (TTM)
- 42.36%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ADMA Performance Chart
ADMA Biologics, Inc. (ADMA) is down 53.0% since the beginning of the year. At $9 per share, ADMA is trading 58.1% below its 52-week high of $20. Investors who bought $1,000 worth of ADMA shares 5 years ago would now be looking at an investment worth $5,163.
Loading charts...
Returns By Period
ADMA Biologics, Inc. (ADMA) has returned -53.02% so far this year and -51.69% over the past 12 months. Over the last ten years, ADMA has returned 2.15% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
ADMA Biologics, Inc.
- 1D
- 3.13%
- 1M
- 4.00%
- YTD
- -53.02%
- 6M
- -56.89%
- 1Y
- -51.69%
- 3Y*
- 30.34%
- 5Y*
- 38.86%
- 10Y*
- 2.15%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
ADMA Monthly Returns History
Based on dividend-adjusted daily data since Oct 17, 2013, ADMA's average daily return is +0.09%, while the average monthly return is +1.53%. At this rate, an investment would double in approximately 3.8 years.
Historically, 48% of months were positive and 52% were negative. The best month was Mar 2016 with a return of +70.3%, while the worst month was Dec 2018 at -54.7%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 5 months.
On a daily basis, ADMA closed higher 45% of trading days. The best single day was Mar 19, 2020 with a return of +40.7%, while the worst single day was Dec 20, 2018 at -45.6%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -5.15% | -10.00% | -42.13% | 13.76% | -22.15% | 7.39% | -53.02% | ||||||
| 2025 | -5.83% | 1.49% | 21.05% | 19.96% | -16.64% | -8.22% | 2.69% | -7.70% | -15.06% | 5.59% | 23.90% | -4.90% | 6.36% |
| 2024 | 14.82% | 3.28% | 23.13% | -1.21% | 46.47% | 17.07% | 9.84% | 40.96% | 15.48% | -18.41% | 23.30% | -14.72% | 279.42% |
| 2023 | -4.90% | -3.79% | -6.76% | 1.21% | 21.49% | -9.34% | 12.47% | -7.23% | -7.01% | -5.59% | 9.47% | 22.16% | 16.49% |
| 2022 | 2.84% | 11.03% | 13.66% | 0.55% | 11.41% | -3.41% | 8.08% | 26.17% | -10.00% | 16.05% | 18.44% | 16.17% | 175.18% |
| 2021 | 13.85% | 4.05% | -23.81% | 11.36% | -10.71% | -8.57% | -3.13% | -13.55% | -15.67% | 14.16% | 6.98% | 2.17% | -27.69% |
Benchmark Metrics
ADMA Biologics, Inc. has an annualized alpha of 12.13%, beta of 0.87, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since October 17, 2013.
- This stock participated in 128.52% of S&P 500 Index downside but only 80.25% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 12.13%
- Beta
- 0.87
- R²
- 0.05
- Upside Capture
- 80.25%
- Downside Capture
- 128.52%
Return for Risk
Risk / Return Rank
ADMA ranks 7 for risk / return — in the bottom 7% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for ADMA Biologics, Inc. (ADMA) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ADMA | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.99 | ||
| Sortino ratioReturn per unit of downside risk | -4.07 | ||
| Omega ratioGain probability vs. loss probability | 0.82 | 1.37 | -0.55 |
| Calmar ratioReturn relative to maximum drawdown | -0.83 | 2.78 | -3.61 |
| Martin ratioReturn relative to average drawdown | -1.66 | 12.44 | -14.10 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the ADMA Biologics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the ADMA Biologics, Inc. was 91.28%, occurring on Oct 11, 2021. Recovery took 691 trading sessions.
The current ADMA Biologics, Inc. drawdown is 65.03%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2021 bear market2021 | -91.28%Oct 2021 | 6y 11mo | 2y 9mo | 9y 8moNov 2014 - Jul 2024 |
2026 bear market2026 | -68.99%Jun 2026 | 1y 1mo | — | 1y 1moApr 2025 - now |
2025 selloff2025 | -31.74%Feb 2025 | 3mo 16d | 2mo 2d | 5mo 18dNov 2024 - Apr 2025 |
2024 bear market2024 | -24.61%Oct 2024 | 12d | 18d | 1moOct 2024 - Nov 2024 |
2013 bear market2013 | -20.47%Dec 2013 | 2mo 6d | 1mo 5d | 3mo 11dOct 2013 - Jan 2014 |
Drawdown Indicators
| ADMA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -91.28% | -56.78% | -34.50% |
Max Drawdown (1Y)Largest decline over 1 year | -62.71% | -9.10% | -53.61% |
Max Drawdown (3Y)Largest decline over 3 years | -68.99% | -18.90% | -50.09% |
Max Drawdown (5Y)Largest decline over 5 years | -68.99% | -25.43% | -43.56% |
Max Drawdown (10Y)Largest decline over 10 years | -86.11% | -33.92% | -52.19% |
Current DrawdownCurrent decline from peak | -65.03% | -1.80% | -63.23% |
Average DrawdownAverage peak-to-trough decline | -53.07% | -10.71% | -42.36% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 31.23% | 2.03% | +29.20% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of ADMA Biologics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how ADMA Biologics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for ADMA, comparing it with other companies in the Biotechnology industry. Currently, ADMA has a P/E ratio of 12.7. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ADMA relative to other companies in the Biotechnology industry. Currently, ADMA has a P/S ratio of 4.1. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ADMA in comparison with other companies in the Biotechnology industry. Currently, ADMA has a P/B value of 5.3. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ADMA
Add ADMA Biologics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ADMA